|Bid||13.94 x 900|
|Ask||13.98 x 1200|
|Day's Range||13.42 - 14.53|
|52 Week Range||10.09 - 37.00|
|Beta (5Y Monthly)||0.35|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
Investors who take an interest in Aimmune Therapeutics, Inc. (NASDAQ:AIMT) should definitely note that the Independent...
From social distancing for patients to company representatives meeting with allergists and payers, the rollout of the drug is anything but normal.
The company said its representatives may not be able to provide support to certain clinics administering the therapy as physicians and patients take precautions to avoid exposure to the virus. The virus outbreak, which originated in Wuhan, China late last year, has infected more than 1,500 Americans and claimed over 60 lives, prompting health agencies to urge people to practice social distancing. The coronavirus outbreak has also affected other companies with new drugs on the market including Amarin Corp Plc, which suspended in-person interactions for its sales representatives until March 30.
Aimmune Announces First U.S. Patients Are Being Treated with Newly-Approved PALFORZIA™, the First Treatment for Peanut Allergy
Aimmune Announces New PALFORZIA™ Data Suggesting Increased Desensitization, Improved Tolerability
The following is a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks that hit 52-week highs on Feb. 26.) Co-Diagnostics Inc (NASDAQ: CODX ) Fate ...
Biotech stocks turned in a lackadaisical performance last week amid earnings releases by smid-cap stocks, a few clinical readouts and data presentations at conferences and a handful of FDA verdicts. Merck ...
The company emerges within weeks of Aimmune Therapeutics Inc. winning the first FDA approval of a peanut allergy treatment.
Aimmune (AIMT) is likely to provide an update on Palforzia's launch plans during Q4 investors' call. The drug gets an approval in January 2020 for the treatment of peanut allergy.
(Bloomberg Opinion) -- It isn’t just Unilever NV that’s struggling to sell more food. Rival Nestle SA now expects to come up short of its self-imposed sales-growth target this year, and it’s counting on acquisitions to put it back on track.While Chief Executive Officer Mark Schneider met the lower end of a goal for underlying operating margin 12 months early, it will take at least another year for the owner of the Nesquik and Nespresso brands to reach and sustain its annual sales growth objective of 4-6%, partly due to the effect of disposals.It’s a rare misstep for Nestle’s first external CEO for almost 100 years. Even with the 2% drop on Thursday, the shares are up more than 40% since his arrival in January 2017, outpacing Unilever. While Schneider’s made a good start selling off underperformers and making purchases in faster growing areas, such as coffee, pet food and meat substitutes, more reshaping is needed. He has traded — either acquired or moved out of — businesses that accounted for about 12% of total sales in 2017. That’s ahead of his target for changing up 10% by the end of 2020. He’s not done yet. From here the focus will be more on acquisitions than disposals.While expanding in the right growth markets is key, Schneider should also go further in pruning the Swiss food giant. Possible culprits for offloading could be parts of the U.S. frozen foods business, especially pizzas, or some water assets, such as those mainstream brands that can’t be taken up market. The fact that Nestle wrote down the value of its Yinlu business in China could be a prelude to an exit from difficult divisions, for example making peanut milk. However, selling off these businesses may be trickier than previous disposals in confectionery, skincare and ice cream.There’s also a risk that Schneider, in an effort to turbocharge growth, becomes less disciplined when he buys. He indicated that he’s open to a wide array of options, the most promising being small or mid-sized purchases, particularly in the hot market for nutrition and metabolism. He lamented that last year was heavy on disposals, but light on purchases. That should change this year, but he shouldn’t be too eager and so strike rash deals.Schneider is comfortable in the pharmaceutical space, having led German healthcare company Fresenius SE before joining Nestle. Medical nutrition not only has higher growth prospects and margins than many food areas, but it is also less constrained by competition rules because Nestle doesn’t have such a big position. He most recently bolstered Nestle’s medical nutrition arm by acquiring gastrointestinal medication Zenpep and increased the investment in Aimmune Therapeutics Inc., which has developed a product to counter the effects of peanut allergies. It indicates that this area, particularly treatments related to the body’s metabolism, is likely to be a bigger focus.To fund any large-scale ambitions, Schneider has Nestle’s stake in L’Oreal SA, worth about 35 billion euros ($38 billion), to play with. The company has always said that it won’t part with this holding unless it has a strategic use for the proceeds, but but he seemed to be more open to an exit on Thursday. Small- to medium-sized deals wouldn’t require any change. A bigger transaction — which can’t be ruled out — might.Either way, Schneider can’t afford to take the wrong turn. Not only is activist Dan Loeb still on the register, but Nestle’s valuation has increased significantly under his tenure. The shares trade on about 22 times forward earnings, compared with about 20 times for Unilever.The premium is justified by Unilever’s recent sales stumble, as well as its slower pace of portfolio change and less focused approach to acquisitions. That doesn’t mean Nestle won’t be punished if it disappoints in the same way as its rival.To contact the author of this story: Andrea Felsted at firstname.lastname@example.orgTo contact the editor responsible for this story: Melissa Pozsgay at email@example.comThis column does not necessarily reflect the opinion of Bloomberg LP and its owners.Andrea Felsted is a Bloomberg Opinion columnist covering the consumer and retail industries. She previously worked at the Financial Times.For more articles like this, please visit us at bloomberg.com/opinionSubscribe now to stay ahead with the most trusted business news source.©2020 Bloomberg L.P.
With NESTLE S A/S ADR (OTC: NSRGY) Health Science's $200-million investment in Aimmune, the company is now adequately funded for the Palforzia launch, settling the bull-bear launch debate, Skorney said in a Thursday note.
Biotechnology investors seeking companies that target allergy treatments should look no further than Aimmune Therapeutics (NASDAQ:AIMT). The company is working on a drug to treat peanut allergies and if successful, it could change the lives of many.Source: Pavel Kapysh / Shutterstock.com Sure, allergists could treat patients with small doses of peanut flour to induce immunity to the allergen. But after the U.S. Food and Drug Administration approved Palforzia, AIMT stock could soar to new heights. There is currently no other drug company that may catch up to Aimmune.So, what is this biotech company worth and when might investors get rewarded by holding AIMT shares?InvestorPlace - Stock Market News, Stock Advice & Trading Tips Third-Quarter ResultsAimmune earned the FDA's support for using Palforzia in children and teens with peanut allergies in the third quarter. It sent job offers to 80 practice account managers, so investors should expect operating costs leading to losses in the near term. Still, the company ended the period with $200.5 million in cash and cash equivalents. Through a loan agreement with KKR (NYSE:KKR), Aimmune may access another $130 million if needed.Aimmune spent $30.6 million on research and development in the quarter. It lost $1.03 a share. General and administrative expenses were $34 million, up from $21.3 million last year. The higher costs are due to staff hiring. The company is able to sustain near-term losses because it has enough cash on hand. The cash balance suggests that the company will not need to sell shares, which would hurt existing shareholders.The company's revenue will start ramping up now that the FDA approved Palforzia as the first treatment for peanut allergies on Jan. 31. With 1.6 million children and teens allergic to peanuts, the drug will generate strong sales over time. The drug is "a complex biologic drug used with a structured dosing approach that builds on a century of oral immunotherapy (OIT) research."Dosing starts in small quantities, which are then gradually increased. When administered this way, the patient is less likely to have an allergic reaction. The dosing range is 0.5 milligrams to 300 milligrams. Revenue PotentialPalforzia will cost $890 a month, so with 1.6 million potential patients, the addressable market is worth $1.4 billion a month. In reality, the drug may cost as low as $20 a month thanks to a company-offered assistance program. And of course, all of those children and teens with peanut allergies are unlikely to just start taking the drug.On its conference call, Aimmune said the upper price range for the treatment was around $20,000. By comparison, other therapies out there that treat non-life threatening conditions cost $3,500. So, with the current price range, management has the flexibility to adjust pricing depending on demand levels.Aimmune will target around 1,300 allergy clinics, divided into two broad categories. The first group of around 200 to 250 allergists have the experience of treating such patients. The second group is physicians who have an individual practice."… the two segments that make up this 1,300 are only the two segments who essentially are both willing and ready to initiate therapy now. They are largely high throughput skit centers and so their ability to do high volume immunotherapy procedures is already in place," CEO Jayson Dallas said. Valuation on AIMT StockSource: Chart by finbox.ioNine analysts who offer a one-year price target think the stock is worth $50.78. Building on the idea that Aimmune may offer a specialty pharmacy model, investors may estimate its future revenue. As it meets the risk evaluation and mitigation strategy (REMS) requirements, the company may have a fair value of $33.50.Aimmune Therapeutics is a potential growth idea for the long term. The near-term risks are lower after the company gained approval for its allergy drug. As revenue increases, the stock should start to trend higher in 2020.As of this writing, Chris Lau did not hold a position in any of the aforementioned securities. More From InvestorPlace * 2 Toxic Pot Stocks You Should Avoid * 7 Utility Stocks to Buy That Offer Juicy Dividends * 10 Gold and Silver Stocks to Profit Off 2020's Fear Trade * 3 Top Companies That Should Be More Careful With Your Data The post Aimmune's Prospects Shine After the FDA Approves Its Allergy Drug appeared first on InvestorPlace.
The funding brings Nestle's total investment to $473 million, increasing the Swiss company's stake to 19.9% of Aimmune's outstanding stock and voting power. Nestle's investment is an incremental positive for Aimmune's shares, which have seen some weakness due to investor worries over financing, Piper Sandler analyst Christopher Raymond wrote in a note. "With this additional investment, we think the prospect of an outright take out by Nestle (or anyone else for that matter) has to be factored in more than before," Raymond said.
The company also lined up a potential $400 million licensing deal for an experimental food allergy drug.
Shares of Aimmune Therapeutics Inc. jumped 9% after the company announced a $200 million investment from Nestlé Health Science on the heels of a Food and Drug Administration approval of Aimmune's peanut allergy treatment. Nestlé has now invested a total of $473 million in Aimmune. The FDA on Jan. 31 approved Palforzia as a treatment for children and teens with peanut allergies, making it the first food allergy drug to be approved by the regulator. The treatment costs $10,680 a year, putting the price on the "high end of expectations," JMP's Liisa Bayko wrote in a Feb. 3 note. Aimmune's stock has gained 22% over the past year, compared with the SPDR S&P Biotech exchange-traded fund , which is up 11%.
Biotech company Aimmune Therapeutics gained Food and Drug Administration approval for a first-of-its-kind peanut allergy treatment, Palforzia, sending AIMT stock rocketing on Monday.